Navigation Links
Revotar Reports First Positive Clinical Results From Phase IIa Study in COPD
Date:10/31/2007

HENNIGSDORF and BERLIN, Germany, October 31 /PRNewswire/ -- Revotar Biopharmaceuticals AG., today announced first positive results from an investigator driven open labelled Phase IIa pilot study in 14 patients with stable COPD stage 0 to II (GOLD criteria) inhaling 70 mg of Bimosiamose twice a day. The study was conducted at the Charite - Medical School Charite Berlin, Prof. Witt and the Respiratory Institute Wiesbaden, Dr. Beeh. The results were presented during the recent European Respiratory Society Meeting in Stockholm in September.

"Despite of the short treatment period we were surprised to see that analysis of induced sputum prior to and after Bimosiamose treatment of 9 days showed that both relative and absolute lymphocytes count decreased significantly. In addition, sputum IL-8 was significantly decreased. The latter is supposed to correlate with the severity of the disease," commented Prof. Dr. Meyer-Sabellek, clinical advisor to Revotar and previously SVP Research&Development at AstraZeneca, Germany. "Inhalation of Bimosiamose twice daily for up to 9 days was well tolerated and safe in patients. This targeted therapy provides the potential to prevent the further progression of inflammatory components in COPD and should be evaluated further in larger clinical trials," added Prof. Dr. Witt from the Charite and the Principal Investigator of the study.

About COPD

Chronic Obstructive Pulmonary Disease (COPD) comprises many serious conditions affecting the lung. More than 30 million people are living with COPD worldwide. COPD is the fourth leading cause of death and is responsible for more than 120,000 deaths a year in the US and Western Europe alone. The disease costs the US healthcare system US$40 billion per year.

About Revotar Biopharmaceutical AG

Revotar develops innovative anti-inflammatory drugs for inflammatory indications such as psoriasis, chronic obstructive pulmonary disease (COPD) and acute lung injury (ALI). Bim
'/>"/>

SOURCE Revotar Biopharmaceutics AG
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...Newswire/ -- BioTrends Research Group, Inc.,releas...M) publication, a,syndicated report offering compr...ia and bone and mineral metabolism in Chronic Kidn... information from 182 US,Nephrologists -- data wer...ne 2008., In the renal anemia market, while the u...
(Date:7/25/2008)...X, CALGARY, July 25 / Resv...X:RVX) is pleased to announce effective,immediatel...irectors. On,the subject of her appointment Jan Gr...xciting opportunity for me. The Company has done a...linical trials. I expect the next,foreseeable futu...
(Date:7/25/2008)...swire-FirstCall/ -- Caraco Pharmaceutical,Laborato...first quarter of,Fiscal 2009, ended June 30, 2008,...or the corresponding period of Fiscal 2008. This r...er of Fiscal 2008. Pre-tax income grew,to $14.6 mi...ared to a,pre-tax income of $9.6 million during th...
(Date:7/25/2008)...25 /- REvolution Computing will,lead ...R product at the,upcoming BioC 2008 conference in ... REvolution Computing Director of Community, Dr. D... Training Manager, and Martin Morgan of,the Fred H...ting,s BioC lab,will introduce participants to the...
Breaking Biology Technology:BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism 2BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism 3Jan Gray Joins Resverlogix Board of Directors 2Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 2Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 3Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 4Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 5Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 6Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 7REvolution Computing Offers Hands-On Tutorial of NWS Parallel Computing Environment at BioC 2008 2
...early peek at what would turn out to be a major ne...the ceiling. , ,As a physics post-doc at the Unive...olds sawed a hole in the ceiling of an office of t...ting a specially built spectrometer through the ro...ear view of a faint glowing gas that permeates the...
...., a provider of information management systems, ...portfolio management and investment accounting sol...rder processing through trade execution, accountin... reporting. , ,Brookfield-based Fiserv designed e...sing dates and the software is capable of managing...
...ice-fishing net, a polymer sorting machine and a B...of a field of 22 inventions University of Wisconsi...Days , Feb. 12 and 13. , ,The projects competed fo...ototype Prize, both sponsored by UW-Madison alumni...e marketplace. , ,We place quite a bit of weight o...
...2004 Conference kicked off today with a high leve... who traveled to Scottsdale for this event which i... new consumer and enterprise technology products. ... international media, venture capitalists, and vet...reneurs introduce new products, and technologies i...
Other Biology Technology:Journey Leads Astronomer to New Galactic Structure 2Journey Leads Astronomer to New Galactic Structure 3UW-Madison Undergrads Shine at Innovation Days 2Entrepreneurs Preview Liberating Technologies 2Entrepreneurs Preview Liberating Technologies 3
(Date:7/24/2008)...sity College of Medicine, Hershey, Pennsylvania ha...inically important immune response modifier with p...nt on the Opioid Growth Factor (OGF)-OGF receptor ...ted in the August 08 issue of Experimental Biolog...ly used drug that may lead to development of new a...
(Date:7/24/2008)... might tell potential suitors, "I like the way you...r look. But worms send their valentines via signal...earchers are now cracking, according to a study pu... . , Scientists from the University of Florida,...echnology and the U.S. Department of Agriculture h...
(Date:7/24/2008)... storage in western U.S. forests , Active fire ...caused a widespread increase in fire-intolerant tr...ng on trees within western U.S. forests. These fac...to account for much of North America,s carbon sink...s, Fellows and Goulden compare California forest i...
(Date:7/23/2008)...ternationally renowned scientists from 12 countrie...alia and India to address ancient microscopic fos...ing together the world,s best scientists in the fi...liam Schopf, founder and director of the UCLA Inst...for the Study of Evolution and the Origin of Life ...
Breaking Biology News(10 mins):Imiquimod, an immune response modifier, is dependent on the OGF-OGFr signaling pathway 2Mate or hibernate? That's the question worm pheromones answer 2Mate or hibernate? That's the question worm pheromones answer 3AGU journal highlights -- July 23, 2008 2AGU journal highlights -- July 23, 2008 3AGU journal highlights -- July 23, 2008 4AGU journal highlights -- July 23, 2008 5AGU journal highlights -- July 23, 2008 6AGU journal highlights -- July 23, 2008 7AGU journal highlights -- July 23, 2008 8UCLA 'world summit' to explore ancient life on Earth, and beyond 2DentaBurst 28TM 29 Freshening Teeth Cleaners Launches Outshine Everyone Video Contest 12052 1DentaBurst 28TM 29 Freshening Teeth Cleaners Launches Outshine Everyone Video Contest 12052 2Moving beyond tamoxifen 3A Drug discovery and the future of selective hormone receptor modulators 12049 1Moving beyond tamoxifen 3A Drug discovery and the future of selective hormone receptor modulators 12049 2French paradox redux 3F US vs French on being full 12046 1Alessi Skin Care Aligns With Celebrity Socialite Fabian Basabe to Raise Awareness for Their Face Forward Campaign 12042 1Alessi Skin Care Aligns With Celebrity Socialite Fabian Basabe to Raise Awareness for Their Face Forward Campaign 12042 2
...ome of patients with type 2 diabetes (DT2) has bee...e of new DNA chip technologies allowing 400,000 DN...s conferring a predisposition to DT2 have been ide...reatic insulin-secreting cells (ZnT8), which is a ...French population was carried out as a French-Brit...
... findings, which are being published the week of F... of the National Academy of Sciences, offer signif...ell as those that lead to abnormal amyloid fibril ...very of novel therapeutic targets for neurodegener... amyloids can play beneficial roles. The subject o...
...ype of protein discovered by Queen’s University re...or antibiotic-resistant bacteria, such as those th... the structure and activity of the protein ?called...rom the departments of Biochemistry and Microbiolo...r new drug development. , “Our group is the fi...
...hers from the Virginia Commonwealth University Mas...arch at the American Association of Cancer Researc...ew combination treatment for chronic lymphocytic l...ant, M.D., Massey,s associate director of translat...d romidepsin (Gloucester Pharmaceuticals) and bort...
Other Biology News:Elucidation of the genome for diabetics with DNA chips 2Elucidation of the genome for diabetics with DNA chips 3Scripps research study reveals structural dynamics of single prion molecules 2Scripps research study reveals structural dynamics of single prion molecules 3Protein discovery targets antibiotic-resistant bacteria 2
Proteinase K Buffer 3.9 ml
Rabbit polyclonal to hCG ( Abpromise for all tested applications). entrezGeneID: 1081 SwissProtID: P01215
Anti-Indolamine (Indoleamine) 2,3-dioxygenase Immunogen: Recombinant human IDO. Available Date: 38454
Glutathione Agarose Beads 10 ml
Biology Products: